#USA #diagnostics #Henderson #VolitionRx #Nu.Q NETs

VolitionRX Limited Outlines a Growth Strategy

VolitionRx Limited, trading under the ticker VNRX on NYSE AMERICAN, has unveiled a forward-looking strategy to become a benchmark in the NETs diagnostics market. The company aims to commercialize its innovative Nu.Q® NETs platform to enhance diagnostics for a variety of critical conditions. According to Chief Commercial Officer Gael Forterre, the year 2025 is pivotal for Volition, with a focus on broad adoption of its capabilities in human diagnostics.

Dual-Pronged Strategy for Commercialization

Volition’s approach involves two main strategies:
1. Licensing Agreements:
The company is negotiating partnerships with leading multinational firms to deploy the Nu.Q® NETs test using their existing laboratory systems. This model builds on the successful application in veterinary diagnostics, prioritizing low capital and operational expenses for both parties. Such partnerships encourage extensive distribution while providing a new revenue channel for the partners while Volition retains its intellectual property. Discussions are already underway with seven potential partners collectively valued at nearly $600 billion, showcasing the substantial market readiness for Volition’s technology.

2. Leveraging CE-mark Approval:
The second facet includes capitalizing on the CE-marked Nu.Q® NETs test, approved for any diseases linked to NETs in Europe. This product is set to be marketed through collaboration with Immunodiagnostic Systems, with an initial revenue stream already recorded from sales in the first quarter of 2025. Orders from nine hospital networks across five countries highlight the early traction and clinical evaluation of its utility in managing a spectrum of NET-related conditions, including sepsis.

Volition’s engineering of its chemiluminescent immunoassay (ChLIA) has paved the way for expanded utility within hospitals, with indications aligning across various medical specialties including sepsis management, complications from surgeries, and autoimmune diseases. Initial FY 2025 reports suggest growing interest, with many institutions looking to incorporate the Nu.Q® NETs test into their routine care practices.

Clinical Applications and Revenue Potential

The company’s plans could envelop a total addressable market exceeding $10 billion annually as the NU.Q® test finds applications well beyond sepsis—spanning trauma care, cardiac issues, and pregnancy management among other medical scenarios. This reflects growing recognition of the critical role that NETosis plays across various health conditions, positioning Volition as a key player in the diagnostics sector.

Future Outlook

In the coming years, Volition aims to increase its global footprint while nurturing partnerships to facilitate comprehensive clinical evaluations and trials. By tapping into innovative technologies and extensive networks, the company seeks to not only broaden access to its diagnostic solutions but also offer invaluable data that enhances treatment protocols globally. As the demand for timely and accurate diagnostics escalates, VolitionRx’s strategies promise significant advancements in patient care through early detection and ongoing monitoring of life-altering diseases.

VolitionRx’s development is one to watch as it aspires to cement its authority in the NETs diagnostics arena, striving towards solutions that save lives and improve health outcomes across the board.